Therapeutic T cell engineering

Michel Sadelain (), Isabelle Rivière and Stanley Riddell
Additional contact information
Michel Sadelain: Memorial Sloan Kettering Cancer Center
Isabelle Rivière: Memorial Sloan Kettering Cancer Center
Stanley Riddell: Fred Hutchinson Cancer Research Center

Nature, 2017, vol. 545, issue 7655, 423-431

Abstract: Abstract Genetically engineered T cells are powerful new medicines, offering hope for curative responses in patients with cancer. Chimaeric antigen receptors (CARs) are a class of synthetic receptors that reprogram lymphocyte specificity and function. CARs targeting CD19 have demonstrated remarkable potency in B cell malignancies. Engineered T cells are applicable in principle to many cancers, pending further progress to identify suitable target antigens, overcome immunosuppressive tumour microenvironments, reduce toxicities, and prevent antigen escape. Advances in the selection of optimal T cells, genetic engineering, and cell manufacturing are poised to broaden T-cell-based therapies and foster new applications in infectious diseases and autoimmunity.

Date: 2017
References: Add references at CitEc
Citations:

Downloads: (external link)
https://www.nature.com/articles/nature22395 Abstract (text/html)
Access to the full text of the articles in this series is restricted.

Related works:
This item may be available elsewhere in EconPapers: Search for items with the same title.

Export reference: BibTeX RIS (EndNote, ProCite, RefMan) HTML/Text

Persistent link: https://EconPapers.repec.org/RePEc:nat:nature:v:545:y:2017:i:7655:d:10.1038_nature22395

Ordering information: This journal article can be ordered from
https://www.nature.com/

DOI: 10.1038/nature22395

Access Statistics for this article

Nature is currently edited by Magdalena Skipper

More articles in Nature from Nature
Bibliographic data for series maintained by Sonal Shukla () and Springer Nature Abstracting and Indexing ().